Discovery of safe and effective gene targets for cellular reprogramming therapies

我们活得更长，但不一定在晚年享有良好的健康。2018年至2020年出生在英格兰的男性和女性预计分别活到79.4岁和83.1岁，但在过去的16.3年和19.3年中，他们的健康状况分别不佳。人口老龄化已经给过度紧张的NHS和社会护理服务带来了巨大的压力。英国将7.8%的GDP用于医疗和护理服务（2018/19）;预计到2030/31年，这一数字将接近或超过GDP的10%。（剑桥生物医学校区），转变生物科学是一个生物技术创业共同创办的首席执行官博士丹尼尔伊韦斯（剑桥大学博士）、CSO Brendan Swain博士（剑桥大学博士）和首席财务官Steve伊韦斯（剑桥连续创业者）。我们的目标是提供第一批安全的细胞再生药物，最终预防与年龄相关的功能衰退，提高患者的健康预期寿命，并减轻健康和护理服务提供者的老龄化负担。Shift Bioscience开发了一项专利-这是一种悬而未决的机器学习方法，使我们能够解开细胞再生途径，并确定安全再生的基因靶点。在Smart的资助下，我们将进一步开发和完善我们的改变游戏规则的平台技术，进行3个实验周期，以发现安全的基因靶点。成功的项目成果将使我们能够谈判制药合作伙伴关系，从而开启改变世界的嫩肤疗法的临床开发。我们的创新与英国创新战略2021中强调的英国优势和机遇的三个优先领域保持一致（AI;生物信息学和基因组学;和工程生物学），并支持两个工业战略挑战基金领域（为老龄化社会开发领先的医疗保健，利用人工智能和数据），同时直接支持英国的使命，以解决英国生命科学愿景2021中强调的老龄化基础生物学问题。

We are living longer, but not necessarily enjoying good health in later life. Men and women born in England in 2018-2020 can expect to live to 79.4 and 83.1 years, respectively, but will spend the last 16.3 and 19.3 years, respectively, in 'not good' health. The ageing population is already placing huge pressures on the overstretched NHS and social care services. The UK spent 7.8% of its GDP on health and care provision (2018/19); this is projected to rise to close to or above 10% of GDP by 2030/31\.Based in the Milner Therapeutics Institute (Cambridge Biomedical Campus), Shift Bioscience is a biotech start-up cofounded by CEO Dr Daniel Ives (PhD University of Cambridge), CSO Dr Brendan Swain (PhD University of Cambridge), and CFO Steve Ives (serial Cambridge-based entrepreneur). Our ambition is to deliver the first drugs for safe cellular rejuvenation, ultimately preventing age-related functional decline, improving healthy life expectancy for patients, and reducing the ageing burden on health and care service providers.Situated at the leading-edge of biomedical science, Shift Bioscience has developed a patent-pending machine learning methodology that enables us to untangle the cellular rejuvenation pathway and identify gene targets for safe rejuvenation. With Smart funding, we will further develop and refine our game-changing platform technology, performing 3 experimental cycles to discover safe gene targets. Successful project outcomes will unlock clinical development of world-changing rejuvenation therapies by allowing us to negotiate Pharma partnerships.Our innovation aligns with three priority areas of UK strength and opportunity highlighted in UK Innovation Strategy 2021 (AI; Bioinformatics and genomics; and, Engineering Biology) and supports two Industrial Strategy Challenge Fund areas (developing leading-edge healthcare for the Ageing Society, exploiting AI and data), while directly supporting the UK's mission to address the underlying biology of ageing highlighted within the UK Life Sciences Vision 2021\.